GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Additional Paid-In Capital

Cellectar Biosciences (FRA:NV4) Additional Paid-In Capital : €228.30 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Additional Paid-In Capital?


Cellectar Biosciences's quarterly additional paid-in capital increased from Sep. 2023 (€183.00 Mil) to Dec. 2023 (€192.63 Mil) and increased from Dec. 2023 (€192.63 Mil) to Mar. 2024 (€228.30 Mil).

Cellectar Biosciences's annual additional paid-in capital increased from Dec. 2021 (€161.57 Mil) to Dec. 2022 (€182.78 Mil) and increased from Dec. 2022 (€182.78 Mil) to Dec. 2023 (€192.63 Mil).

Cellectar Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Cellectar Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Additional Paid-In Capital Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 107.63 132.78 161.57 182.78 192.63

Cellectar Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.23 179.48 183.00 192.63 228.30

Cellectar Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cellectar Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Additional Paid-In Capital
Comparable Companies
LGVN SLS SKYE FIXX SYBX PRTG UBX VYNE BIOR NXTC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
CLRB:USA
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Website
https://www.cellectar.com
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines